Bone Mineral Density News and Research

RSS

Exercise helps retain greater bone density: Researchers

The stage for osteoporosis is set well before menopause-but exercise can help rewrite the script, according to Medical College of Georgia researchers.

26 Apr 2010

Controlling actions of FSH may help treat osteoporosis in menopausal women

Diminished bone density is common among menopausal women and raises their risk of osteoporosis, bone fractures and subsequent complications. Research has traditionally focused on therapies that seek to maintain the level of estrogen in the body. This hormone seems to sustain bone health, but it drops to an extremely low level during and after menopause.

26 Apr 2010

Lipocine announced receipt of $2M development milestone payment from Abbott

Lipocine Inc. announced today the receipt of a $2 million development milestone payment from Abbott under the terms of its Licensing Agreement to develop and commercialize an oral testosterone product for hypogonadism, also known as low testosterone.

21 Apr 2010

Novartis Pharma AG initiates second Phase I trial for oral PTH1-34: Emisphere Technologies

Emisphere Technologies, Inc. today announced that Novartis Pharma AG has initiated a second Phase I trial for an oral PTH1-34 which uses Emisphere's Eligen Technology, and is in development for the treatment of postmenopausal osteoporosis. Emisphere Technologies is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen Technology.

16 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Increasing calcium intake is a common--yet not always successful--strategy for reducing bone fractures. But a study supported in part by the Agricultural Research Service (ARS) underscores the importance of vitamin D and its ability to help the body utilize calcium. The study also may explain why increasing calcium alone isn't always successful in dealing with this problem.

12 Mar 2010

Post-marketing safety studies for LABAs: AstraZeneca confident of SYMBICORT in treatment of asthma

On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT® (budesonide/formoterol fumarate dihydrate).

12 Mar 2010

Domiciliary parenteral nutrition helps children with serious intestinal problems live more normally

Children with serious intestinal problems have to be fed intravenously. There moreover, exist systems that enable intravenous feeding to be carried out at home. Mr I-aki Irastorza, paediatrician at the Cruces hospital in Bilbao, spent some 15 years analysing how serious intestinal problems in children were treated at the Great Ormond Street Children's Hospital in London. With the gathered data he has presented a highly novel PhD thesis at the University of the Basque Country.

9 Mar 2010

Soccer can be effective training method to reduce bone weakening that comes with increasing age

The observed improvements in bone mineral density, strength and postural balance due to recreational soccer are of particularly interest for a large group of women but also for elderly men, says project leader Associate Professor Peter Krustrup, University of Copenhagen, and continues "It is well known that the risk of falls and fractures increases with age as a result of weaker bones, poorer balance and attenuated ability to trigger rapid muscle force, but the present results suggest that soccer - and possibly other ball games - is an effective training method to reduce bone weakening that comes with increasing age".

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Soy isoflavone tablet does not prevent bone loss in postmenopausal women

A previous six-month study by Iowa State University researchers had indicated that consuming modest amounts of soy protein, rich in isoflavones, lessened lumbar spine bone loss in midlife, perimenopausal women.

10 Feb 2010

Beer may help prevent osteoporosis

A new study suggests that beer is a significant source of dietary silicon, a key ingredient for increasing bone mineral density. Researchers from the Department of Food Science & Technology at the University of California, Davis studied commercial beer production to determine the relationship between beer production methods and the resulting silicon content, concluding that beer is a rich source of dietary silicon. Details of this study are available in the February issue of the Journal of the Science of Food and Agriculture, published by Wiley-Blackwell on behalf of the Society of Chemical Industry.

8 Feb 2010

MaMayo Clinic experts available to discuss health issues and concerns related to Olympic Games

Mayo Clinic's medical experts are sources of in-depth expertise and commentary about health issues and background related to the Olympic Games and Olympians. Below is a sampling of Mayo Clinic experts available to discuss numerous topics related to the Olympic Games, including concussions, performance enhancing drugs, sports psychology, joint injuries, etc. Mayo has satellite capability for broadcast requests.

21 Jan 2010

Study analyses physiological parameters of athletes

The maximum time an athlete is able to continue climbing to exhaustion may be the only determinant of his/her performance. A new European study, led by researchers from the University of Granada, the objective of which is to help trainers and climbers design training programmes for this type of sport, shows this to be the case.

9 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

$HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture$

HIV-infected postmenopausal women face higher risk for accelerated bone loss and fracture

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), postmenopausal HIV-infected women have a high prevalence of low bone mineral density and high bone turnover placing them at high risk for future bone fractures.

5 Jan 2010